PR – Alligator Bioscience

2023-06-302023-07-03

Phase 2 results indicate durability of response for Alligator’s CD40 agonist

BioStock interview with Alligator CMO, Sumeet Ambarkhane. Following the second round of interim results from OPTIMIZE-1, the phase 2 trial w ...

2018-10-022022-09-20

Tasuku Honjo & James Allison share the 2018 Nobel Prize in Physiology or Medicin. Photo: Wikimedia CommonsOn Monday October 1st the Nobe ...

2016-07-082022-09-20

Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for tumor-directed immunotherapy. ...

2016-05-202022-09-20

Alligator Bioscience has received the SwedenBIO Award for ”exceptional achievements within the life-science industry”. This is yet another c ...

2016-04-222022-09-20

Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of canc ...

2016-03-302022-09-20

After proofreading minor corrections has been made. Comprehensive income and Financial position are however intact. Complete proposal, item ...

2016-03-042022-09-20

Major shareholders have now submitted their proposals regarding items 8 and 9 in the published notice. Proposal item 8: The number of board ...

2016-02-152022-09-20

The shareholders of Alligator Bioscience AB (publ), Reg. No 556597-8201, are hereby invited to attend the extraordinary shareholder’s meetin ...

2015-08-122022-09-20

Alligator Bioscience AB, a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of cancer ...